Search

Aim: To compare the symptoms and signs of patients with chronic venous disease with the objective results of duplex ultrasound and plethysmography (foot volumetry)., Methods: One hundred and one patients with symptomatic chronic venous disease were investigated with duplex ultrasound and foot volumetry. Patients were classified according to the CEAP classification and the symptoms of pain, heaviness, tiredness, ankle swelling and night cramps were graded. The severity of the disease was judged objectively by the reflux time (sum of reflux time at 6 levels) and the venous function was measured globally with expelled volume (ml) and refilling rate (Q) (ml/100 mlxmin) after exercise, and expelled volume related to foot volume (EVrel), (ml/100 ml). The ratio Q/EVrel)was calculated. Correlation was calculated between clinical class, symptoms and objective parameters., Results: The correlation analyses showed a clear constant relationship between the CEAP clinical classification and the foot volumetry measures (Q/EVrel), r=0.48; p<0.01) There was no such relationship between clinical class and the sum of duplex calculated reflux time (r=-0.05), or between foot volumetry and reflux time. There was no correlation between the clinical class and the total score of symptoms (r=0.044)., Conclusion: The clinical class of CEAP classification correlates significantly with foot volumetry parameters. There is no correlation between clinical class and reflux time. The severity of the venous disorder and subsequently the need for treatment is more accurately judged by foot volumetry as a global measure. Clinical classification has a realistic meaning concerning the functional evaluation of venous disease.

Aim: Vasogen's immune modulation therapy (IMT)* involves the ex vivo exposure of a sample of autologous blood to 3 oxidative stress factors (heat, an oxidative environment, and ultraviolet light), followed by intramuscular re-injection. The primary objective of this study was to assess the effect of Vasogen's IMT on skin blood flow in patients with symptomatic peripheral arterial occlusive disease (PAOD)., Methods: In a double-blind, placebo-controlled pilot study, 18 patients with moderately advanced PAOD were randomized to receive 2 courses each of 6 intramuscular injections of either saline or Vasogen's IMT over a 9-week period. Dorsal foot skin blood flow was assessed directly using laser Doppler fluxmetry (LDF) and indirectly using measurement of transcutaneous pO(2) (tcpO(2)). Key outcome measures of skin blood flow were, for LDF: resting values, peak postischemic values, and the total time to reach peak values following release from 4 min of total foot ischemia and, for tcpO(2): resting values and the time for tcpO(2) to reach 50% of the pre-ischemia value. Measurements were carried out at baseline, at weeks 3, 6, and 9, and at 2 months post-therapy., Results: No significant differences were detected between groups for resting or peak postischemic LDF values for dorsal foot skin blood flow. Patients randomised to IMT experienced a progressive decrease in the time to peak postischemic skin blood flow, reaching statistical significance at 2 months. Treated patients experienced a 26.1 s decrease in time to peak blood flow (p=0.026) vs a 7.9 s decrease in the placebo group (p=ns). Similar but less striking results were achieved for tcpO(2) recovery time to 50% of pre-ischemia values (treated group, p=0.035; placebo group, p=ns)., Conclusion: Vasogen's IMT improved recovery rates of postischemic dorsal foot skin blood flow in a group of patients with moderately advanced PAOD, probably due to improved endothelial function.

The purpose of this study was to analyze long-term costs for foot ulcers in diabetic patients. Patients were treated and followed prospectively by a foot care team. A retrospective economic analysis was performed of costs for 274 patients during 3 years from healing of an initial foot ulcer, with or without amputation. Costs were estimated for inpatient care, outpatient care, home care, and social service. The cost calculations include costs due to complications and disability related to the initial ulcer, costs related to recurrence of ulcer, and costs for prevention of new ulcers. Expected total present value cost per patient during 3 years of observation was $26,700 (U.S. dollars) for primary healed patients with critical ischemia and $16,100 for primary healed patients without critical ischemia. For patients who healed with an amputation, the corresponding costs were $43,100 after a minor amputation and $63,100 after a major amputation. When estimating the costs for diabetic foot ulcers, it is not sufficient to calculate short-term costs. Long-term costs are high, mainly due to the need for increased home care and social service, but also due to costs for recurrent ulcers and new amputations.

All diabetic patients aged 15-50 years (n = 395) in the county of Umeå (population 118,500) were invited to have a standardized foot examination and 380 (96%) attended. Three-quarters (78%) had Type 1 diabetes, 20% Type 2 diabetes, and 1% secondary diabetes. They were compared with 100 healthy control subjects. Both Type 1 and Type 2 diabetic patients had slight or moderate loss of forefoot arches more often than control subjects (57% and 60% vs 31%, p less than 0.001). Callosities were not significantly more common in diabetic patients than in control subjects. Lesions observed on the lower legs and feet of the Type 1 and Type 2 diabetic patients were Melin's shin spots (33% and 39%), dry feet (33% and 29%), yellow toenails (27% and 31%), purpura (9% and 5%), ulcers (3% and 0%), necrobiosis (3% and 0%), and diabetic osteopathy (2% and 0%). Intermittent claudication was present in 1% and 3%, respectively. Three Type 1 diabetic patients had undergone below-knee amputation. Two of the control subjects had Melin's shin spots. With the exception of necrobiosis which was only found in women with Type 1 diabetes and Melin's shin spots which were twice as common in diabetic men as women, whether Type 1 or Type 2, lesions were equally distributed between the sexes. Sensory thresholds for vibration, perception, and pain were significantly elevated in Type 1 diabetic patients with dry feet, fallen forefoot arches or hammer toes compared with those without. They were not increased in Type 2 diabetic patients or control subjects with these lesions.(ABSTRACT TRUNCATED AT 250 WORDS)